Fingerprint
Dive into the research topics of 'Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: Quality-of-life assessment'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: Quality-of-life assessment
Xiaolei Zhou*, David Cella, David Cameron, Mayur M. Amonkar, Anthony Segreti, Steven Stein, Mel Walker, Charles E. Geyer
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
47
Scopus
citations